Recall Register

Food, drugs, devices › American Health Packaging

Drug recall: Oxycodone Hydrochloride Oral Solution, USP (C-II), 5 mg/5 mL, Delivers 5 mL per Cup, 1 Tray of 10 Cups, Rx Only, For Ins

FDA enforcement event 89670 · Class II · initiated 22 Feb 2022 · status Terminated · terminated 16 Jul 2023

DrugVoluntary: Firm initiated1 product recordColumbus, OH

FDA enforcement event 89670 is a drug recall by American Health Packaging of Columbus, OH, initiated 22 Feb 2022 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 65% of the 325 drug enforcement events initiated in 2022 carry the same class.

Status: Terminated, terminated 16 Jul 2023. Initiation: voluntary: firm initiated. American Health Packaging has 42 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

American Health Packaging, Columbus, OH.

Reason for recall

"Impurity failure at 0-time of the repackaged lot."

Distribution

"Nationwide in the USA"

Product records

Recall numberProductQuantityClassStatusReport date
D-0652-2022Oxycodone Hydrochloride Oral Solution, USP (C-II), 5 mg/5 mL, Delivers 5 mL per Cup, 1 Tray of 10 Cups, Rx Only, For Institutional Use Only, American Health Packaging, Columbus, OH 43217. UPC (01) 003 60687 406 40 4; Case NDC#: 60687-406-77, Unit Dose NDC#: 60687-406-4089,880 unit-dose cupsClass IITerminated16 Mar 2022

Context

65%of 2022 drug events are Class II325 events that year
1product record in this eventfirm median: 1
42events on this register for the firm

Other enforcement events for American Health Packaging

InitiatedProduct (first record)TypeClassRecords
19 Aug 2026Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, CDrugClass III1
3 May 2022Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals), 100 mg, 100 Capsules (10 x 10), 10-count blisters per card, 10DrugClass III1
12 Apr 2022Cyanocobalamin Injection, USP, 1000 mcg per mL, For Intramuscular or Subcutaneous Use Only, 25 x 1 mL Vials, Rx only, MaDrugClass III1
20 Dec 2021Metoprolol Succinate Extended-Release Tablets, USP 50 mg, 500-count bottle, Rx Only, Manufactured by: Alkem LaboratoriesDrugClass II1
17 Sep 2021GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx oDrugClass II1
15 Sep 2021Valproic Acid Oral Solution, USP, 500 mg/10 mL, 100 10 mL unit dose cups per case, Rx Only, Packaged and Distributed by:DrugClass II1
12 May 2021Sirolimus Tablets 1 mg, 30 Tablets (5 blister cards x 6 unit doses), Rx only, Packaged and Distributed by: American HealDrugClass III1
7 Jan 2021Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg, 100 per carton (10 capsules x 10 blister cards), Rx onlDrugClass II1
10 Jun 2020Nabumetone Tablets, USP, 500 mg, 100 Tablets per carton (10 tablets x 10 blister cards), Rx only, Distributed by: AmericDrugClass III1
19 May 2020Doxycycline Hyclate Tablets, USP, 100 mg, 30 Tablets per carton (3 x 10), Rx only, Distributed by: American Health PackaDrugClass II1

All 42 events for American Health Packaging

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Impurity failure at 0-time of the repackaged lot."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide in the USA"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 16 Jul 2023. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.